| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.049 | 0.4 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.4 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |